Equities analysts expect Intec Pharma Ltd (NASDAQ:NTEC) to report earnings of ($0.28) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Intec Pharma’s earnings, with the highest EPS estimate coming in at ($0.25) and the lowest estimate coming in at ($0.33). Intec Pharma reported earnings of ($0.34) per share in the same quarter last year, which would indicate a positive year over year growth rate of 17.6%. The company is expected to report its next earnings results on Wednesday, August 21st.

According to Zacks, analysts expect that Intec Pharma will report full-year earnings of ($1.05) per share for the current financial year, with EPS estimates ranging from ($1.15) to ($0.98). For the next year, analysts forecast that the company will report earnings of ($0.85) per share, with EPS estimates ranging from ($1.03) to ($0.67). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Intec Pharma.

Intec Pharma (NASDAQ:NTEC) last announced its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.32) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.05.

A number of equities research analysts recently issued reports on the company. BidaskClub raised Intec Pharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 23rd. Oppenheimer set a $15.00 price objective on Intec Pharma and gave the stock a “buy” rating in a report on Friday, February 22nd. LADENBURG THALM/SH SH restated a “buy” rating and set a $15.00 price objective on shares of Intec Pharma in a report on Thursday, February 28th. Maxim Group reiterated a “buy” rating and issued a $12.00 price target on shares of Intec Pharma in a report on Tuesday, February 19th. Finally, Zacks Investment Research upgraded Intec Pharma from a “sell” rating to a “hold” rating in a report on Tuesday, February 5th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Intec Pharma currently has an average rating of “Buy” and a consensus target price of $12.17.

NTEC stock opened at $5.16 on Thursday. Intec Pharma has a 1 year low of $3.55 and a 1 year high of $9.25.

Several institutional investors have recently made changes to their positions in NTEC. PRW Wealth Management LLC acquired a new stake in shares of Intec Pharma during the fourth quarter valued at about $29,000. Reilly Financial Advisors LLC acquired a new stake in shares of Intec Pharma during the fourth quarter valued at about $38,000. BlackRock Inc. acquired a new stake in shares of Intec Pharma during the fourth quarter valued at about $67,000. Marshall Wace North America L.P. acquired a new stake in shares of Intec Pharma during the first quarter valued at about $117,000. Finally, Delek Group Ltd. acquired a new stake in shares of Intec Pharma during the first quarter valued at about $154,000. Institutional investors own 33.81% of the company’s stock.

Intec Pharma Company Profile

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.

Featured Story: What is an overbought condition?

Get a free copy of the Zacks research report on Intec Pharma (NTEC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intec Pharma (NASDAQ:NTEC)

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.